ProKidney Corp.
NASDAQ:PROKBiotechnology
+$0.02 today
- Market cap
- $349.70M
- Beta
- 1.70
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.53
Volume 1.80M
Average 0.96M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
ProKidney Corp.
NASDAQ:PROK
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +207.7% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +207.7% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Travere Therapeutics, Inc. NASDAQ:TVTX | $4.86B | $50.65 | Overvalued | -235.0 | +41.80% |
Maze Therapeutics, Inc. NASDAQ:MAZE | $1.88B | $34.33 | Not rated | -11.0 | -12.21% |
Ardelyx, Inc. NASDAQ:ARDX | $776.74M | $3.09 | Not rated | -24.5 | -43.99% |
DiaMedica Therapeutics Inc. NASDAQ:DMAC | $474.01M | $8.79 | Not rated | -8.8 | +17.67% |
Jyong Biotech Ltd. Ordinary Shares NASDAQ:MENS | $133.81M | $1.76 | Not rated | -25.1 | -93.62% |
Unicycive Therapeutics, Inc. NASDAQ:UNCY | $97.25M | $3.55 | Not rated | -40.8 | -35.44% |
Continue the stock analysis
Jump to another research area for this company.